Ultomiris is a longer-acting monoclonal antibody also made by Alexion Pharmaceuticals that may be used to treat PNH, aHUS, gMG, and NMOSD (see How does Ultomiris compare to Soliris for PNH?).Eculizumab REMSEculizumab is available only under a special program called the Ultomiris and Soliris ...
Before you can receive SOLIRIS, your healthcare provider must: enroll in the REMS program; counsel you about the risk of serious meningococcal infections; give you information about the signs and symptoms of serious meningococcal infection; make sure that you are vaccinated against serious infections...
SOLIRIS is only available through a program called the SOLIRIS REMS.SOLIRIS may also increase the risk of other types of serious infections. If one’s child is treated with SOLIRIS, make sure that the child receives vaccinations against Streptococcus pneumoniae and Haemophilus influenzae type b (...
“This approval represents a major advancement in the treatment of pediatric myasthenia gravis and provides hope to families navigating this complex disease,” saidSharon Hesterlee, PhD, Chief Research Officer, MDA. “The availability of S...
Under the Soliris REMS, prescribers must enroll in the program (5.2). Enrollment in the Soliris REMS program and additional information are available by telephone: 1-888-SOLIRIS (1-888-765-4747). 1 1.1 INDICATIONS AND USAGE Paroxysmal Nocturnal Hemoglobinuria (PNH) Soliris is indicated for the...
Epysqli is available only through a restricted program under a REMS called Epysqli REMS, because of the risk of serious meningococcal infections. Further information is available at www.EpysqliREMS.com or 1-866-318-8144. Other Infections ...
Patients may only access the therapy through a restricted program under a Risk Evaluation Management Strategy (REMS) program, called Ultomiris and Soliris REMS, because of the risk of serious meningococcal infections. To be eligible, patients must complete or update their meningococcal vaccine(s) at...
Under the Soliris REMS, prescribers must enroll in the program. Prescribers must counsel patients about the risk of meningococcal infection, provide the patients with the REMS educational materials, and ensure patients are vaccinated with meningococcal vaccine(s). ...
Under the Soliris REMS, prescribers must enroll in the program. Prescribers must counsel patients about the risk of meningococcal infection, provide the patients with the REMS educational materials, and ensure patients are vaccinated with meningococcal vaccine(s). ...